Adara Ventures Announces First Close of €100M AV4 Fund, Targeting Cybersecurity, AI & Digital Infrastructure
Adara Ventures, the European venture capital firm specialising in early-stage deep tech investments, today announced the first close of its fourth flagship fund, AV4, targeting €100 million in capital commitments. This new fund reinforces Adara’s commitment to delivering strong returns in strategic sectors, including cybersecurity, applied AI, digital infrastructure, hardware components, digital health, and space.
“We are immensely proud to announce the successful first close of AV4,” said Nico Goulet, Founding Partner of Adara Ventures. “Over the past nine months, we have secured in excess of €140 million in commitments across our fourth-generation funds. Alongside AV4, this includes Adara Ventures Energy (AVE), our first Pan-European fund dedicated to energy transition technologies. In one of the most challenging fundraising environments of the past 20 years, our strong DPI record, disciplined investment strategy, and focused fund model make AV4 a compelling opportunity for our limited partners.”
Goulet continued: “In a sector obsessed with unicorns, our philosophy has always been to maximise ‘dragons’—companies that return the entire fund. We are proud to have generated at least one dragon in each of our previous fund generations, with AV2 poised to rank among the top 5% of VC funds in Europe for its vintage.”
Since its inception in 2005, Adara Ventures has invested in over 50 pioneering companies across Europe and the U.S., achieving more than 10 notable exits. Adara is backed by over 130 limited partners, including institutional investors, pension funds, asset managers, high-net-worth individuals, and family offices. “We are especially proud to welcome new anchor investors in this first close, as well as a new generation of Adara portfolio founders investing as LPs — a true testament to the strength of our value proposition,” Goulet added.
Adara is now actively investing from AV4 and AVE, with plans to complete the first three investments in each fund within the first half of 2025. Both funds remain open to new investors.
About Adara Ventures
Adara Ventures partners with visionary founders who have strong vision, courage, and execution capabilities. Founded in 2005, the firm manages more than €350 million in assets. Adara’s portfolio focuses on early-stage companies with a European footprint, specialising in cybersecurity, data applications and infrastructure, hardware components, digital health, space and energy transition technologies. For more information, visit www.adara.vc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313203598/en/
Contacts
Media Contact
Ross Strachan
+34 914517070
info@adara.vc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mark Wiseman appointed Chairman of Alter Domus18.3.2025 07:00:00 EET | Press release
Alter Domus, the leading global provider of tech-enabled fund services for the private equity, real assets and private debt sectors today appointed Mark Wiseman as Chairman. Mr. Wiseman is the former Head of Active Equities and Chairman of BlackRock’s Alternatives Business, as well as President & CEO of Canada Pension Plan Investment Board (CPPIB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317232851/en/ Mark Wiseman Following a successful tenure, René Beltjens will step down as Chairman but will retain his seat on the Board. As alternatives specialists, with $3 trillion assets under administration (AUA), Alter Domus’ end-to-end servicing expertise enables asset managers to focus on investing and creating outsized returns for investors. Alter Domus’ leadership in alternatives and market share growth has been achieved by significant investments in fund administration services and debt capital market solutions. As a tec
Brisbane Airport embraces advanced analytics from Cirium Sky Warehouse18.3.2025 00:00:00 EET | Press release
Brisbane Airport (BNE), which serves as the major gateway to Queensland, has partnered with aviation analytics firm, Cirium, to become one of the first airports to integrate Cirium Sky Warehouse, a data-driven cloud platform, into its modernisation efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317052819/en/ Brisbane Airport Cirium’s advanced data and analytics will be seamlessly integrated with Brisbane Airport’s business systems. This integration will support enhanced capacity planning, resource allocation, and operations analysis. Jeremy Bowen, Cirium CEO, commented: "We are delighted to support Brisbane Airport’s transformative investment to revolutionise its passenger experience and meet future travel demand. “Integrating Cirium data and analytics through the Cirium Sky Warehouse will help the airport to consolidate and accelerate digitization, leading to improved decision-making and operational performance.
Trump-Inspired World Liberty Financial Closes $550 Million Across Token Sales17.3.2025 21:37:00 EET | Press release
World Liberty Financial, Inc. (“WLFI”), the developer of a pioneering DeFi protocol and governance platform inspired by Donald J. Trump, has made history with the completion of the second set of its token sales, totaling $550 million in gross proceeds in concurrent U.S. and non-U.S. token offerings. After launching on October 15, 2024, WLFI has successfully concluded two sets of token sales in concurrent U.S. and non-U.S. offerings. In the first set, $300 million USD of WLFI tokens were sold between the offerings, and in the second set, $250 million USD of WLFI tokens were sold between the offerings. Between all the offerings, $550 million USD in WLFI tokens have been sold. More than 85,000 total participants in the token sales underwent Know Your Customer (KYC) process to determine participation eligibility. "This milestone proves that those who truly understand crypto and finance recognize what we’re building — and that WLFI is on track to supercharge DeFi as it transforms global fin
RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product17.3.2025 21:28:00 EET | Press release
RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/ RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege. “The results from this ongoing international multicenter study are exceeding expectations, showcasing remarkable outcomes. We are profoundly optimisti
Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 203017.3.2025 20:00:00 EET | Press release
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance. Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases. Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response. In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom